Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

The Prostate(2020)10.1002/pros.23955Source: DataRank Database

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer is a research paper published in The Prostate (2020). On theSindex it has a DataRank of 0. It has been cited 37 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access37 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: greenTopics (36)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Eugene Shenderov ORCID,Mario A. Eisenberger ORCID,Sushant K. Kachhap ORCID,Drew M. Pardoll ORCID,Samuel R. Denmeade ORCID

Live enrichment

PubMed:31972048 PMC:PMC7585736

Prostate Cancer Foundation

Grant: Challenge Award

Prostate Cancer Foundation

Grant: Young Investigator Award

National Institutes of Health

Grant: P30 CA006973

NCI NIH HHS

Grant: R01 CA184012

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

greenLicense: Wiley Online Library User Agreement

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7585736

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.23955

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23955

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/pros.23955

https://doi.org/10.1002/pros.23955

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansNeoplasm MetastasisBenzamidesNitrilesPhenylthiohydantoinTestosteroneAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesFrameshift MutationGerm-Line MutationMaleProgrammed Cell Death 1 ReceptorProstatic Neoplasms, Castration-ResistantPoly(ADP-ribose) Polymerase InhibitorsAbiraterone Acetate

Keywords

TestosteroneDNA repairImmunotherapyprostate cancerMaleProgrammed Cell Death 1 ReceptorAbiraterone AcetatePoly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsBenzamidesNitrilesPhenylthiohydantoinHumansNeoplasm MetastasisFrameshift MutationGerm-Line MutationRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good health

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

FAIR Checklist

Authors (7)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)